 Shares of Merrimack Pharmaceuticals Inc. MACK, 224.14 skyrocketed 199.5 toward a 4 12-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, 1.39 IPN, 3.85 said overnight that its Onivyde pancreatic cancer treatment met the primary endpoint of a Phase 3 trial. Ipsen said it plans to file a supplemental New Drug Application NDA with the U.S. Food and Drug Administration for Onivyde. 